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OBJECTIVES We sought to determine the relationship between geographical miss (GM) and edge
restenosis (ERS) following intracoronary radiation therapy.
BACKGROUND Edge restenosis may be a limitation of intracoronary irradiation to prevent in-stent restenosis
(ISR). Inadequate radiation source coverage of the injured segment (GM) has been proposed
as a cause of ERS. We studied the relationship between GM and ERS following 192Ir
treatment of ISR.
METHODS There were 100 patients with native vessel ISR in WRIST (Washington Radiation for
In-Stent Restenosis Trial), in which patients with ISR were first treated with conventional
techniques and then randomized to gamma irradiation (192Ir) or placebo. Geographical miss
was defined as segments proximal or distal to the treated lesion that were subjected to injury
during primary intervention but were not covered by the radiation source.
RESULTS Geographical miss was documented in 56 of 164 edges (34%). Edge restenosis was noted at
eight of 80 radiated edges and in four of 84 placebo edges. In the irradiated group, ERS was
observed in 21% of edges with GM and in 4% of edges without GM (p 5 0.035). In contrast,
in the placebo group, ERS was observed in only 7% of edges with GM and in 4% of edges
without GM (p 5 NS). The late edge lumen loss was higher in the irradiated group with GM
as compared to placebo with GM (0.74 6 0.57 vs. 0.41 6 0.50 mm, p 5 0.016).
CONCLUSIONS Edge restenosis following gamma irradiation treatment of ISR is related to GM: a mismatch
between the segment of artery injured during the primary catheter-based intervention and the
length of the radiation source. (J Am Coll Cardiol 2001;37:1026–30) © 2001 by the
American College of Cardiology
In-stent restenosis (ISR) has become an important clinical
problem because of the exponential increase in the use of
intracoronary stents (1,2). Adjunctive intracoronary radia-
tion therapy (IRT) using both beta and gamma emitters has
been shown to reduce the recurrence rate of ISR (3–6).
However, a common pattern of recurrent edge restenosis
(ERS) is found in patients with IRT failure (7). Edge
restenosis was initially observed with the use of radioactive
32P stents (activities of 3–20 mCi) (8–10) and more recently
with the use of catheter-based systems (7,11).
The exact mechanisms of ERS are still under investiga-
tion. It has been proposed, however, that low dose radiation
may stimulate proliferation at the edge of the treatment
zone, which is injured during primary intervention (9,12–
14). Failure at the edge of a treatment zone has been
described in radiation oncology reports (15) and the term
geographical miss (GM), that is, inadequate coverage of the
diseased segment, has been applied.
The purpose of the current study was to determine the
relationship between GM and ERS following gamma irra-
diation treatment for ISR.
METHODS
Patients and procedure. The Washington Radiation for
In-Stent restenosis Trial (WRIST) was a placebo-
controlled protocol in which patients with ISR were first
treated with conventional catheter-based techniques and
then randomized to receive either gamma irradiation (192Ir)
or placebo (dummy seeds). There were 100 patients with
native vessel ISR. Patients without angiographic follow-up
or with total occlusions at follow-up were excluded. Angio-
graphic analysis was available in 42 patients from the
irradiated group and 44 patients from the placebo group.
The details of WRIST have been presented elsewhere
(6). In brief, angiographic entry criteria included diameter
stenosis (DS) $50% in vessels 3 to 5 mm in diameter with
lesion lengths ,47mm treated successfully (,30% residual
stenosis without complications). Devices used during the
primary intervention included balloon, ablative devices (ex-
cimer laser angioplasty [spectranetics], or rotational atherec-
tomy [SCIMED]), additional stents or a combination
thereof. All procedural steps were documented angiographi-
cally. Following the primary intervention, patients were
randomly assigned to receive a nylon ribbon (0.003 in.
diameter) containing either placebo or 192Ir seeds (Best
Medical International, Springfield, Virginia); sources con-
tained five, nine or 13 seeds that covered 19, 36 and 51 mm,
respectively. The prescribed dose was 15 Gy to a distance of
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2 mm from the center of the source for vessels 3 to 4 mm in
diameter or 18.5 Gy to 2 mm from the center of the source
for vessels .4 mm in diameter.
Definitions and angiographic analysis. Intracoronary ni-
troglycerin (200 mg) was administered before each angio-
gram. Cineangiograms at follow-up were acquired using the
same projections of the procedural angiograms. All proce-
dural and follow-up cineangiograms were analyzed at the
Washington Hospital Center Angiographic Core Labora-
tory by observers blinded to the treatment strategy. Cine
frames were selected at the end-diastolic phase from the two
sharpest and most severe projections of the stenosis before
and after the procedure and at six-month follow-up. Quan-
titative angiographic analysis was performed with the CMS-
GFT system (Medis) (16). The contrast-filled catheter was
used for image calibration (17).
The overall angiographic results from WRIST have
previously been reported (6). The minimal lumen diameter
(MLD) at each edge was measured. Acute edge lumen gain
was defined as the change of MLD at each edge from pre-
to postintervention; late edge lumen loss was defined as the
change of MLD at the edges from postintervention to
follow-up at six months.
The investigators attempted to angiographically docu-
ment all the steps of the intervention, including the position
of the radiation to determine whether the edge of the
radiated segment was injured. Edge restenosis was defined
as a follow-up DS $50% occurring #5 mm proximal or
distal to the last seed of the radiation source (Fig. 1).
Geographic miss was defined as segments proximal or distal
to the treated lesion that were subjected to injury during
balloon inflation or new stent implantation but were not
covered by the last seeds of the radiation source.
Statistical analysis. Continuous variables are presented as
mean 6 SD; ordinal variables are presented as frequencies.
A comparison between continuous variables was performed
using the Student t test with the Bonferroni correction for
multiple comparisons. Comparisons between ordinal vari-
ables were performed using the chi-square or Fisher exact
test. In order to control the within-patient effects, a gener-
alized estimation equation modeling analysis, using patients
as subjects, was performed. A p value ,0.05 was considered
significant.
RESULTS
Eighty-six irradiated coronary arteries and 172 edges (two
edges per irradiated segment) in 86 patients were eligible for
the study. However, eight edges were excluded because of
the ostial location of the proximal end of the source in the
right coronary artery. Thus, 164 edges were analyzed.
Overall, GM was documented in 56 of 164 edges (34%). In
the irradiated group, GM was observed in 28 of 80 (35%)
edges induced by balloon dilation (n 5 17) or additional
stent implantation (n 5 11). Geographic miss in the placebo
group was observed in 28 of 84 (33%) edges induced by
balloon dilation (n 5 18) or stent implantation (n 5 10).
The frequency of GM was similar among the proximal and
distal segments in the irradiated and placebo groups. Edge
restenosis was noted at eight of 80 radiated edges (two
proximal, four distal, and one both proximal and distal) and
in four of 84 placebo edges (two proximal and two distal).
The relationship between GM and ERS is shown in
Table 1. In the irradiated group, ERS was observed in 21%
of edges with GM and in 4% of edges without GM (p 5
0.035). In contrast, in the placebo group ERS was observed
in only 7% of edges with GM and in 4% of edges without
GM (p 5 NS). Generalized estimation equation analysis,
which was used to account for within-patient effect, showed
that in radiation-treated patients the probability of ERS
depended on the GM (p 5 0.021), but not on distal/
proximal lesion location (p 5 0.397). For the placebo-
treated patients, the probability of ERS did not depend on
either GM (p 5 0.481) or lesion location (p 5 0.971).
Quantitative angiographic analysis of the 164 edges is
presented in Table 2. The preintervention, postintervention
and follow-up reference diameters were similar in all four
Abbreviations and Acronyms
DS 5 diameter stenosis
ERS 5 edge restenosis
GM 5 geographical miss
IRT 5 intracoronary radiation therapy
ISR 5 in-stent restenosis
MLD 5 minimum lumen diameter
SCRIPPS 5 Scripps Coronary Radiation to Present
Proliferation Post-Stenting Trial
WRIST 5 Washington Radiation for In-Stent
Restenosis Trial
Figure 1. Schematic representation of geographical miss (GM) and edge
restenosis (ERS). (Top) During the procedure, the proximal segment
represented GM (1) (treated lesion subjected to injury but not covered by
the radiation catheter) and the distal segment represented GM (2) (treated
lesion covered adequately with the radiation catheter). (Bottom) At
follow-up this proximal edge with GM developed ERS and the distal edge
without GM showed no ERS.
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groups. The preintervention MLDs were also similar in all
four groups.
192Ir lesions with and without GM. Acute gain was larger
at the edges with GM than in those without GM (p ,
0.0001). This was built into the definition, because a treated
edge would no doubt be larger than an untreated edge. As
a result, the postintervention edge MLD was larger at edges
with GM (p 5 0.0065). Late edge lumen loss was greater in
the 192Ir group with GM than in the 192Ir group without
GM (p , 0.0001). At follow-up, the edge MLD was
smaller at the sites of GM (p 5 0.0023).
Placebo lesions with and without GM. Similar to the
192Ir group, acute gain was larger at edges with GM than in
edges without GM (p 5 0.007). As a result, the postinter-
vention edge MLD was larger at sites with GM (p 5
0.0064). Late edge lumen loss was greater in the placebo
group with GM (p 5 0.010). At follow-up, the edge MLD
was similar in lesions with and without GM (p 5 NS).
192Ir versus placebo lesions with GM. Acute edge lumen
gain and postintervention edge MLD were similar in 192Ir
versus placebo lesions with GM. However, late edge lumen
loss was greater in the 192Ir lesions than in the placebo
lesions (p 5 0.016). As a result, the follow-up edge MLD
was smaller in the 192Ir versus placebo lesions (p 5 0.039).
DISCUSSION
The current study identifies edge restenosis as a cause of
failure in using 192Ir brachytherapy to prevent recurrent
ISR. Although the mechanism of ERS remains unclear, it
occurred in 21% of edges in which the 192Ir source did not
adequately cover the entire segment of artery injured during
the primary catheter-based treatment of ISR (Fig. 2). This
is the definition of GM (15).
Frequency of ERS. The incidence of ERS after initial
stent implantation without radiation has been reported to be
between 5% and 10% (18,19). The incidence of ERS after
treatment of in-stent restenotic lesions without radiation is
less clear; reports vary from 15.3% in the placebo group of
the SCRIPPS (Scripps Coronary Radiation to Prevent
Proliferation Post-Stenting) trial (3,20) to only 3% to 4% in
the control arms of WRIST (6) and GAMMA 1 (21).
The first reports of ERS following brachytherapy were
related to the use of the 32P-radioactive stent (8–10). In
these patients ERS was seen four to six months after implan-
tation and was located at or near the margins of the stent. The
pronounced ERS in these patients has been called the “candy-
wrapper” effect (10). Conversely, in SCRIPPS, a randomized,
placebo-controlled, clinical trial similar to WRIST, the fre-
quency of stent margin restenosis with 192Ir was similar to
placebo (3,20). The major effect of gamma irradiation appeared
to be the reduction of in-stent neointimal tissue.
The current study addressed the question whether
gamma irradiation treatment of ISR is associated with an
increased incidence of edge effect. In the current analysis,
the incidence of ESR in the 192Ir arm was 10.0% and 4.7%
in the placebo arm. This difference did not reach statistical
significance, as it may be because the event rate was low.
However, when more sensitive angiographic indices were
analyzed (i.e., late edge lumen loss and follow-up edge
MLD), gamma irradiation had a negative impact on stent
edge lumen dimensions compared with placebo. This in-
creased late edge lumen loss and the smaller follow-up edge
MLD after brachytherapy indicate that the edge effect after
gamma irradiation is not simply an illusion due to the
absence of neointimal formation within the length of the
stent (as suggested by the SCRIPPS trial) (3).
Table 1. Relationship Between Geographical Miss and Edge
Restenosis in Irradiated (192Ir) and Placebo Groups
n ERS (1) ERS (2)
192Ir
GM (1) 28 6 (21%) 22 (79%)
GM (2) 52 2 (4%) 50 (96%)
Placebo
GM (1) 28 2 (7%) 26 (93%)
GM (2) 56 2 (4%) 54 (96%)
ERS 5 edge restenosis; GM 5 geographical miss.















Value GM (1) GM (2)
Preintervention (mm)
Reference diameter 2.57 6 0.42 2.64 6 0.45 NS 2.61 6 0.59 2.63 6 0.38 NS NS NS
Edge MLD 2.01 6 0.38 2.08 6 0.37 NS 2.00 6 0.45 2.03 6 0.33 NS NS NS
Postintervention (mm)
Reference diameter 2.68 6 0.41 2.72 6 0.44 NS 2.70 6 0.59 2.72 6 0.38 NS NS NS
Edge MLD 2.34 6 0.47 2.09 6 0.38 0.0065 2.30 6 0.48 2.05 6 0.35 0.0064 NS NS
Follow-up (mm)
Reference diameter 2.63 6 0.39 2.65 6 0.44 NS 2.66 6 0.60 2.61 6 0.40 NS NS NS
Edge MLD 1.60 6 0.51 1.96 6 0.48 0.0023 1.89 6 0.50 1.97 6 0.45 NS 0.039 NS
Changes of luminal diameter (mm)
Acute edge lumen gain 0.33 6 0.20 0.01 6 0.30 , 0.0001 0.30 6 0.47 0.02 6 0.45 0.007 NS NS
Late edge lumen loss 0.74 6 0.57 0.13 6 0.42 , 0.0001 0.41 6 0.50 0.08 6 0.61 0.010 0.016 NS
GM 5 geographical miss; MLD 5 minimal lumen diameter; NS 5 not specified.
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GM and edge stenosis. The current study also addressed
the question of whether GM contributes to ERS following
gamma irradiation treatment for ISR. The concept of GM
has been adopted from the field of radiation oncology to
explain treatment failure due to inadequate doses delivered
to the tumor margins (15). When applied to lesions treated
with brachytherapy, GM refers to those cases in which there
was a mismatch between the length of the radiation source
and the length of the segment of the coronary artery injured
by the primary interventional procedure. There are two
potential causes of this mismatch: inadequate 192Ir source
length or overly aggressive primary intervention. At the time
that patients were enrolled into the current study, there were
few data concerning the “edge effects” of brachytherapy.
Therefore, no measures were taken to minimize the poten-
tial problem of inadequately covering the artery’s entire
segment injured during primary intervention. Although the
radiation protocol mandated source coverage of at least
5 mm proximal and distal to the end of each lesion, up to
34% of the treated arteries had GM. In contrast, the current
analysis contains substantial evidence of overly aggressive
primary intervention. In both the 192Ir and placebo groups,
the acute edge lumen gain and postintervention edge MLD
were larger in lesions with GM, which was built into the
definition because a treated edge would no doubt be larger
than an untreated edge. In addition, in some of these cases
GM was a result of additional post-brachytherapy catheter-
based intervention in order to optimize the acute angio-
graphic results. The increased late edge lumen loss in the
placebo with GM versus the placebo without GM probably
reflects this increased injury.
Possible mechanism of ERS. The precise mechanism of
ERS is not well understood. Serial intravascular ultrasound
studies indicate that it is a combination of neointimal
proliferation, negative remodeling (9,11) and/or longitudi-
nal plaque displacement (22,23).
In the 32P-emitting stent, the candy-wrapper effect is
mostly a result of neointimal proliferation (24). After 32P
beta irradiation plus nonradioactive stent implantation,
ERS is caused by neointimal proliferation in lesions without
GM and negative remodeling in lesions with GM (25).
Depending on the source, ERS can be explained simply as
a fall in dose to the point where it is inadequate to inhibit
the restenosis process. However, others have suggested that
low doses in fact stimulate neointimal formation at seg-
ments subjected to trauma (9,11). Weinberger et al. (26)
reported a dose-dependent effect using intracoronary 192Ir
radiation prior to overstretch injury in the pig model; there
was a significant stimulatory effect at 10 Gy and a marked
reduction of neointima formation at .15 Gy. In this study,
the finding that the late edge lumen loss in the treated GM
edges is greater than that in untreated GM edges, leading to
a significant difference in edge MLD, indicates this is not a
passive phenomenon but an active phenomenon. This
paradoxical stimulation of neointimal formation at a lower
than therapeutic dose is a problem confronting vascular
radiation therapy in general.
Limitations. This study contains a number of limitations.
First, the number of patients that were treated and subse-
quently developed ERS was too small to detect differences
for the binary restenosis. However, when more sensitive
angiographic indices were analyzed (i.e., late edge lumen
loss and follow-up edge MLD), radiation clearly had a
negative impact on edge lumen dimensions compared with
placebo. Second, radiation dose clearly falls off at the last
seed and may increase the rate of GM. Dosimetry analysis
of the last seed in the ribbon (3 mm) detected a 25%
decrease in the cumulative dose compared with a seed in the
center of the ribbon. However, because the therapeutic
window is unknown, we elected to consider GM beyond the
last seed when it was clear that there was no sufficient
therapeutic dose at the injured segment. Third, it is possible
that not all injured segments were captured with the use of
ablative devices. This analysis is therefore limited to the
documented injury performed by balloon inflation. Never-
theless, this study did not detect any device-specific contri-
bution to the incidence of edge effect.
Conclusions and clinical implications. Edge restenosis
following gamma irradiation treatment of ISR is related to
GM: a mismatch between the segment of artery injured
during the primary catheter-based intervention and the
length of the radiation source. This suggests that careful
Figure 2. An example of GM induced by balloon dilation, not covered by radiation catheter, presenting with edge stenosis at six-month follow-up. (A)
Diffuse lesion located in the right coronary artery. (B) One of the balloon dilatations (between arrows) performed during the intervention. (C) The radiation
delivery catheter in place (between arrows) proximal to the balloon injured segment. (D) Final result. (E) Six-month follow-up: reduction in lumen at the
edge with geographical miss (between arrows).
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attention to the distribution of the treatment, confining it to
the stenosed segment with maximal coverage of the treated
segment with radiation sources, should be taken in order to
avoid ERS.
Reprint requests and correspondence: Dr. Ron Waksman, 110
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